Latest 10-K annual reports

Merck reports modest 2025 sales growth driven by oncology and animal health, while facing significant patent expirations and IRA pricing pressures on key products, alongside strategic acquisitions and pipeline advancements.

Sotera Health Company reported a 5.7% increase in net revenues to $1,163.6 million for 2025, alongside significant legal settlements and ongoing environmental litigation.

MarketAxess reports increased trading volumes and revenues in 2025, driven by strategic acquisitions and platform enhancements, despite a decline in net income and diluted EPS.

Huron Consulting Group Inc. reported an 11.9% increase in revenues before reimbursable expenses to $1.66 billion in 2025, alongside strategic acquisitions and a significant share repurchase program.

Jackson Financial Inc. reports a net loss for 2025 but demonstrates strong adjusted operating earnings and strategic capital management initiatives, including a new partnership with TPG and increased share repurchases.

Bowhead Specialty Holdings Inc. announced a 24% increase in gross written premiums and a 40.6% rise in net income for 2025, despite a notable decrease in underwriting income and an uptick in its loss ratio.

Corcept Therapeutics reports strong 2025 revenue growth driven by Korlym sales, despite an FDA Complete Response Letter for relacorilant in hypercortisolism, while oncology programs show promising advancements.

First Solar's 2025 annual report highlights significant revenue growth and strategic manufacturing expansion, despite a complex global trade and regulatory environment.

National Bank Holdings Corporation reported a net income of $109.6 million for 2025, or $2.85 per diluted share, and completed the acquisition of Vista Bancshares, Inc., expanding its asset base to $12.4 billion pro forma.

Jazz Pharmaceuticals plc reports a 5% increase in total revenues for 2025, driven by strong growth in rare oncology and epilepsy products, despite declines in oxybate sales due to generic competition.

SLR Investment Corp. reports a net increase in net assets from operations of $92.5 million for fiscal year 2025, alongside significant investment activity and improved asset coverage, despite a decrease in gross investment income.

Revvity, Inc. reported a 4% revenue increase in fiscal year 2025, driven by Diagnostics and Software, but faced declines in net income and gross margins due to tariffs and restructuring costs.

NRG Energy's 2025 results reflect strategic acquisitions and shareholder returns amidst a decline in net income and operating cash flow.

American Tower Corporation reports steady revenue growth in 2025, driven by property operations and data centers, while navigating legal disputes and strategic divestitures.

Gladstone Land Corporation's 2025 annual report reveals a decrease in fixed lease revenue offset by a significant rise in participation rents and successful property sales, alongside ongoing challenges in certain crop markets.

Xenia Hotels & Resorts reports significant net income and RevPAR growth in 2025, driven by strategic dispositions and portfolio improvements.

International Business Machines Corporation reported robust financial performance in 2025, exceeding expectations with significant revenue growth, expanded profit margins, and strong cash generation, driven by its hybrid cloud and AI strategy.

FibroBiologics, a clinical-stage biotech, reported increased net losses and a going concern doubt for 2025, while advancing its fibroblast-based therapies and addressing Nasdaq listing compliance.

Tandy Leather Factory, Inc. reported a significant increase in net income for fiscal year 2025, driven by a gain from the sale of its corporate headquarters and improved sales, despite an operating loss.

PC Connection, Inc. reported a 2.5% net sales increase to $2.87 billion in 2025, but net income declined by 3.9% and operating cash flow significantly decreased.

Xometry, Inc. announced a 26% revenue increase to $686.6 million in 2025, driven by marketplace expansion and a shift to Adjusted EBITDA profitability.

Day One Biopharmaceuticals reports significant revenue growth from its newly approved pediatric brain tumor therapy, OJEMDA, while strategically expanding its oncology pipeline through key acquisitions and licensing deals.

EverQuote, Inc. reported a significant financial turnaround in 2025, achieving $99.3 million in net income and 38.5% revenue growth, driven by strong performance in its automotive and home insurance verticals.

Lucid Group reports increased revenue in 2025 driven by vehicle deliveries and new models, but continues to face substantial net losses and high operating costs, necessitating ongoing capital raises.

Onto Innovation Inc. reported a 2% revenue increase to $1.005 billion for fiscal year 2025, driven by strategic acquisitions, but saw a 32.1% decline in net income due to higher operating costs and inventory write-downs.

Carlyle Secured Lending reported a significant increase in its investment portfolio to $2.5 billion in 2025, driven by strategic acquisitions, despite a decline in net investment income and NAV per share.

ConnectOne Bancorp, Inc. reported a significant increase in net income and total assets for 2025, primarily driven by the acquisition of The First of Long Island Corporation, despite a decrease in diluted EPS.

Option Care Health, a leading provider of home and alternate site infusion services, reported a 13% increase in net revenue to $5.65 billion for the fiscal year ended December 31, 2025, despite a slight dip in net income.

Myriad Genetics reported a significant net loss of $365.9 million in 2025, driven by substantial impairment charges and a 2% revenue decrease, despite strategic advancements in its testing portfolio.

Douglas Dynamics, Inc. reported a 15.4% increase in net sales to $656.1 million for 2025, driven by higher volumes in both Work Truck Solutions and Work Truck Attachments, alongside a strategic acquisition and refinancing of debt.